Contribute Try STAT+ Today

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going.

And here is our regular feature in which we highlight a different person each week. This time around, we note that Precigen (PGEN) hired Gaurav Vij as head of business development. Previously, he worked at Gilead Sciences (GILD), where he was senior director, corporate development.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Why print so few of these. Endpoint News includes 4x as many. A disservice to both readers and subscribers sending in the personnel changes.

    • Hi Barbara,

      Thanks for the note.

      And here’s the answer to your question which, by the way, is the first time I’ve received this complaint since I began Pharmalot in 2007.

      I regularly forage for what I call comings and goings each week. I rely on folks sending me notices, whether it’s a public relations person or an employee who wants to fill me in on some changes. When time permits, I’ll hunt down a change that I hear about and try to confirm it. Often, announcements are distributed by services and automatically land in my mailbox.

      But as you might imagine, each week can vary. If you do a search on our site – use the words ‘up,’ ‘down’ and ‘ladder – you’ll see what I mean. There have been many occasions when the Ladder has lots of rungs.

      Take October. This week we had 14 items, which was fewer than 19 the week before. Two weeks ago, there were 27 listed. Three weeks ago, there were 31 listed. (Perhaps you missed those).

      I understand your point and I want folks who read us to feel they are getting good value. I don’t know what your litmus test is for “so few,” but if you based your conclusion on this week alone, I would say you either missed earlier ‘ladder’ posts, or your bar is very high. And that’s fine. But I do what I can.

      In any event, I’m happy to post as many as possible. If there are more job changes, I certainly want to hear about them, whether it’s a formal announcement or something that has to be conveyed surreptitiously. So tell your friends and neighbors. I stand at the ready.

      Hope this helps and stay safe,
      ed at pharmalot

Comments are closed.

Your daily dose of news in health and medicine

Privacy Policy